Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dihydrocodeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 12/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.74 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrocodeine SCHEMBL12402838 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL13380391 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL18569649 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL12960899 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL10440393 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL12402837 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL6064584 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL6123622 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL19615457 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL14516219 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | DURECT CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12509469-B2 | Compositions and methods for the treatment of pain and dependence disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-12-30 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-12433877-B2 | Sustained release drug delivery systems and related methods | DURECT CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536138-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-2129683-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE AND OTHER DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090011030-A1 | BREAKTHROUGH PAIN MANAGEMENT | AKELA PHARMA SRL (BB) | 2009-01-08 | — | — | US | disclosed |
| EP-1996218-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008106429-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE AND OTHER DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106689-A2 | BREAKTHROUGH PAIN MANAGEMENT | LAB INTERNATIONAL SRL (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964564-A1 | Breakthrough Pain Management | LAB International SRL (BB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008002971-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007101161-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-4089855-A | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby | CORNELL RESEARCH FOUNDATION, INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | SLC10A2, OPRK1, HBB | OPRM1 5/4885OPRD1 63/4885OPRK1 2/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRM1 4810/4885OPRD1 4518/4885OPRK1 2862/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | OPRM1 57/4885OPRD1 67/4885OPRK1 11/4885 |
| US-12509469-B2 | Compositions and methods for the treatment of pain and dependence disorders | OPRD1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 4/4885 |
| US-12433877-B2 | Sustained release drug delivery systems and related methods | OPRM1, OPRK1, SLC7A5 | OPRM1 1/4885OPRD1 17/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.